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Senseprimer consequently, no change in amino-acid sequence results from the introduced mutation. The RARαF fragment and pSG5 mRARαCE∆T were both digested with XhoI/HindIII, gel purified, and ligated to generate pSG5 mRARαCF.
The RARα2AB fragment and pSG5 mRARαCF were both digested with MfeI/Tth111I, gel purified, and ligated to generate pSG5 mRARα2AF for expression of full-length RARα2. The PML∆CT fragment and pSG5 MCS were digested with MfeI/HindIII and EcoRI/HindIII, respectively, gel purified, and ligated to generate pSG5 mPML∆CT.
The pSG5 mPML∆CT and pSG5 mRARαCF were both digested with Tth111I/XbaI, gel purified and ligated to generate pSG5 mPML-RARα (see the Appendix for complete aminoacid sequence of the expressed transgene). The sequences of the primers are listed in the appendix. The ligated products were each transformed into competent DH5α bacteria and plated on ampicillin containing LB agar plates for overnight incubation at 37°C. DNA was isolated from resistant colonies and confirmed by restriction analysis to contain inserts of the expected sizes. In addition, the coding region of each construct was verified by sequencing to contain the desired DNA sequence.
